It has been demonstrated that higher expression of CAV-2 and its upstream regulator bromodomain containing 4 (BRD4) is associated with shorter overall survival of 76 pancreatic cancer patients [44]. This evidence concerns the gene CAV2 and pancreatic neoplasm.